Spinal cord injury drug eases DNA damage in mouse model of Alzheimer's

A small molecule that already cleared human safety testing for spinal cord injury reduced neuronal DNA damage and brain inflammation in Alzheimer's mice, King's College London researchers report, though the study involved only a handful of animals and has not yet been tested in Alzheimer's patients.

Researchers at King's College London report that KCL-286, an orally available drug that activates the retinoic acid receptor beta (RARb) pathway, reduced neuronal DNA damage and dialed down inflammatory activity in the brains of Tg2576 mice, a strain bred to develop Alzheimer's-like amyloid pathology. The findings, published July 8, 2026 in FEBS Open Bio, showed the drug increased activity of a DNA repair protein called BRCA1 and lowered a marker of DNA double-strand breaks, gamma-H2AX, in neurons; it also normalized the shape of microglia and astrocytes, brain cells associated with inflammation, according to the paper.

The study is preliminary and small. Mice, aged 15 to 18 months and already carrying established amyloid plaques, were given the drug or a vehicle solution by injection three times a week for roughly three months, with only three animals per treatment group, the paper states. What makes KCL-286 notable is not the mouse result alone but its regulatory history: the same compound already completed a Phase 1 human safety and tolerability trial for spinal cord injury, published in 2023 in the British Journal of Clinical Pharmacology, meaning any future Alzheimer's trial could in principle skip the earliest safety-testing stage required of a brand new drug.

King's College London neuroscientist Jonathan Corcoran, a senior author on the new paper, said in the university's release that the drug's prior clearance "will dramatically cut down the traditional multi-year timeline required for new drug development." No trial of KCL-286 in people with Alzheimer's disease has been announced. The Phase 1 data establish that the drug was tolerated by healthy volunteers for a different condition; they say nothing about whether it is safe or effective in older adults with Alzheimer's, nor about whether the DNA repair and anti-inflammatory effects seen in mice would occur, or matter, in a person's brain.

Corcoran and colleagues, whose funding came from the Medical Research Council and the Wellcome Trust, described the results as supporting further investigation into RARb activation as a therapeutic strategy, not as evidence the approach works in humans.